Cannabis products with a higher ratio of THC relative to CBD show the most consistent pain relief in clinical research, particularly for nerve-related pain. But “what works” depends heavily on the type of pain you have, how you consume it, and the full chemical profile of the product, not just whether the label says indica or sativa.
Why Cannabis Affects Pain at All
Your body has its own pain-regulation system called the endocannabinoid system, and THC essentially hijacks it. Your cells have two types of cannabinoid receptors. The first type, found throughout the brain and spinal cord, controls how pain signals travel between nerve cells. When THC activates these receptors, it reduces the release of chemical messengers that carry pain signals, essentially turning down the volume on pain. The second type of receptor sits primarily on immune cells and plays a role in inflammation.
CBD works differently. It doesn’t bind strongly to either receptor but appears to influence pain through other pathways, including effects on inflammation and serotonin signaling. The practical result: THC tends to be the stronger pain reliever on its own, while CBD may support pain relief with fewer mind-altering effects.
THC-Dominant Products Have Stronger Evidence
A 2025 systematic review of cannabis for chronic pain found that products with comparable or high THC-to-CBD ratios produced small but measurable improvements in pain, primarily for neuropathic (nerve) pain. Products with low THC relative to CBD did not improve pain outcomes. This is a consistent finding across multiple reviews: THC appears to be the more important cannabinoid for pain relief, and CBD-only products have weaker evidence for treating pain on their own.
A phase 3 clinical trial published in Nature Medicine tested a full-spectrum cannabis extract for chronic low back pain and found a meaningful reduction of 1.9 points on a 10-point pain scale, with even stronger results for participants who had a neuropathic component to their pain. Notably, this was a whole-plant extract containing multiple cannabinoids and terpenes, not isolated THC, which supports the idea that the full chemical profile matters.
When compared directly to opioids for chronic non-cancer pain, cannabis showed roughly similar pain relief but with an important advantage: people using cannabis were significantly less likely to quit treatment because of side effects. That doesn’t make cannabis a miracle alternative, but it does suggest a more tolerable side-effect profile for some people.
Indica vs. Sativa: What Actually Matters
In surveys of regular cannabis users, indica strains are consistently preferred for pain relief. There’s a chemical reason for this. Indica strains typically have higher levels of a terpene called myrcene, which produces a sedating, body-focused effect often described as a “body high.” Strains with more than 0.5% myrcene tend to produce this calmer, more physically relaxing experience, which many people find helpful for chronic pain, joint pain, arthritis, and nerve pain.
Sativa strains, with lower myrcene and relatively more THC than CBD, tend to produce a more energizing, cerebral effect. Some users prefer them for acute pain, migraines, and headaches where sedation isn’t desirable. But the indica/sativa distinction is really a rough shorthand for the underlying chemical profile. Two strains labeled “indica” can have very different cannabinoid and terpene compositions. If you have access to lab-tested products, the actual THC-to-CBD ratio and terpene content tell you far more than the strain category.
Terpenes That Contribute to Pain Relief
Terpenes are aromatic compounds that give cannabis its smell and flavor, but they also appear to have their own pain-relieving properties. The most studied for pain include:
- Myrcene: the most abundant terpene in many cannabis strains, associated with sedation and muscle relaxation. High levels are typical in indica-leaning strains.
- Beta-caryophyllene: has anti-inflammatory and pain-relieving effects in animal studies. It was once thought to directly activate cannabinoid receptors on immune cells, though newer research questions that mechanism.
- Linalool: also found in lavender, it shows anti-inflammatory properties in preclinical research.
- Limonene: demonstrates dose-dependent pain relief in animal models, with some evidence it interacts with opioid pathways.
One important finding: a study of high-CBD cannabis extract found greater pain relief than pure CBD or pure THC alone, suggesting that the combination of cannabinoids and other plant compounds (likely including terpenes) produces stronger effects than any single molecule. Scientists call this the “entourage effect,” and it’s why full-spectrum products often outperform isolates in pain research.
Minor Cannabinoids Worth Knowing About
Beyond THC and CBD, cannabis contains dozens of lesser-studied cannabinoids. CBN, a breakdown product of THC that forms as cannabis ages, is mildly psychoactive and may have analgesic and anti-inflammatory effects. A 2025 living systematic review noted a small trial testing a topical product combining THC, CBD, and CBN for diabetic neuropathy that showed improved pain versus placebo. However, the evidence is still considered insufficient because it comes from a single small trial. CBG is another minor cannabinoid generating interest, but rigorous pain-specific data remain thin.
How You Consume It Changes the Experience
The method of consumption dramatically affects how quickly you feel relief and how long it lasts.
Inhaling cannabis (vaping or smoking) produces effects within 5 to 10 minutes, making it the fastest route. This makes it practical for breakthrough pain or flare-ups. The tradeoff is that effects wear off faster, typically within 2 to 3 hours. Vaping is generally preferred over smoking because it avoids combustion byproducts.
Edibles take roughly 2 hours to reach peak concentration in the blood. The slow onset makes it harder to find the right dose, since people often take more before the first dose has fully kicked in. But effects last much longer, often 6 to 8 hours, which can be useful for sustained overnight pain relief.
Sublingual products (oils or tinctures held under the tongue) fall in between, reaching peak levels in roughly 40 to 60 minutes. They bypass some of the digestive processing that slows down edibles, offering a middle ground between speed and duration.
Topical products are applied directly to the skin and work locally without producing a high. Early research on topical formulations for knee osteoarthritis and diabetic neuropathy shows some promise, but the evidence base is still very limited.
Starting Doses for Pain
Clinical dosing protocols for chronic pain follow a “start low, go slow” principle. One widely referenced approach suggests beginning with 5 mg of CBD twice daily and only adding THC if CBD alone is insufficient. If THC is needed, it starts at just 2.5 mg per day, increasing by 2.5 mg every few days until you find the dose that helps without unacceptable side effects. The upper range explored in clinical settings is around 40 mg per day for each cannabinoid.
For people who have used cannabis before or who need faster relief for severe pain, a balanced THC:CBD product at 2.5 to 5 mg of each, taken once or twice daily, is a common starting point. For people who are sensitive to medications or new to cannabis, the increases are smaller (1 mg of THC at a time) and spaced further apart (weekly instead of every few days).
Tolerance develops with regular use. Daily cannabis use within the past month is generally considered enough to produce partial tolerance to cognitive side effects, meaning experienced users can typically handle higher doses with less impairment.
What the Evidence Honestly Shows
The International Association for the Study of Pain, the world’s largest professional organization focused on pain, has reviewed the full body of evidence and does not endorse cannabis as a general pain treatment. Their concern isn’t that cannabis doesn’t work for anyone; it’s that high-quality clinical trials are still too scarce to make broad recommendations. As their task force chair noted, this “is not a door closing on the topic” but a call for more rigorous research to identify which patients benefit most, what doses work best, and what the long-term safety profile looks like.
The practical reality is that millions of people use cannabis for pain and report meaningful relief, particularly for neuropathic pain, inflammatory conditions, and chronic pain that hasn’t responded well to other treatments. The gap between lived experience and clinical endorsement reflects the difficulty of studying cannabis in controlled settings, not necessarily a lack of real-world benefit. If you’re considering cannabis for pain, the strongest evidence points toward THC-containing products (not CBD-only), full-spectrum formulations, careful dose titration, and realistic expectations of modest rather than dramatic improvement.